IRWD

#2387
Ironwood Pharmaceuticals, Inc. - Class A Common Stock
3.5 7 USD
-0.83%
Сектор: Здравоохранение
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
3.57
3.57
Годовой диапазон
0.56
5.78
Дневное изменение
-0.83%
Месячное изменение
-14.59%
6-месячное изменение
+2.88%
Годовое изменение
+475.81%
Предыдущее закрытие
3.6 0
Open
3.5 7
Low
3.5 7
High
3.5 7
Volume
137
Открыть полный график Full chart

Financials

Обзор Отчетность Статистика
Квартал Год
  • Market Capitalization 587.67 M
  • Employee 100
  • Founded 1998
  • CEO N/A
  • Website www.ironwoodpharma.com
  • Headquarter Delaware, United States
  • FIGI BBG000GBZ3J2
  • Industry Производители лекарств — специализированные и дженерики
Общий доход
Чистая прибыль
Базовая прибыль на акцию
Общий долг
Свободный денежный поток
Денежные средства и эквиваленты
Коэффициент цена/прибыль
5.85
Коэффициент цена/денежный поток
1.67

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc. Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler’s diarrhea. By 2004 the company had raised $99M and was preparing a Phase I trial for linaclotide.

Новости